1. Home
  2. SCZM vs COLL Comparison

SCZM vs COLL Comparison

Compare SCZM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCZM

Santacruz Silver Mining Ltd. Common Shares

N/A

Current Price

$7.64

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$32.42

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCZM
COLL
Founded
N/A
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SCZM
COLL
Price
$7.64
$32.42
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$51.17
AVG Volume (30 Days)
540.9K
547.7K
Earning Date
05-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.73
Revenue
N/A
$780,567,000.00
Revenue This Year
$22.30
$5.93
Revenue Next Year
$69.17
N/A
P/E Ratio
$14.27
$19.32
Revenue Growth
N/A
23.62
52 Week Low
$6.90
$23.23
52 Week High
$17.65
$50.79

Technical Indicators

Market Signals
Indicator
SCZM
COLL
Relative Strength Index (RSI) 34.66 24.32
Support Level $6.90 $31.01
Resistance Level $12.74 $32.92
Average True Range (ATR) 0.67 1.30
MACD -0.05 -0.04
Stochastic Oscillator 17.80 1.07

Price Performance

Historical Comparison
SCZM
COLL

About SCZM Santacruz Silver Mining Ltd. Common Shares

Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: